Arizona State Retirement System Atara Biotherapeutics, Inc. Transaction History

Arizona State Retirement System

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 27, 2023	BUY	$2.8 - $5.46 $2,058 - $4,013	735 Added 3.25%	23,367 $67,000
Q4 2022 Feb 07, 2023	BUY	$2.85 - $5.18 $3,012 - $5,475	1,057 Added 4.9%	22,632 $74,000
Q3 2022 Nov 07, 2022	BUY	$2.85 - $8.73 $370 - $1,134	130 Added 0.61%	21,575 $82,000
Q2 2022 Jul 28, 2022	BUY	$4.69 - $9.84 $5,299 - $11,119	1,130 Added 5.56%	21,445 $167,000
Q1 2022 May 04, 2022	BUY	$8.44 - $16.89 $7,806 - $15,623	925 Added 4.77%	20,315 $189,000
Q4 2021 Feb 04, 2022	SELL	$14.7 - $19.89 $1,131 - $1,531	-77 Reduced 0.4%	19,390 $306,000
Q3 2021 Nov 12, 2021	BUY	$11.99 - $17.9 $1,774 - $2,649	148 Added 0.77%	19,467 $348,000
Q2 2021 Aug 02, 2021	SELL	$12.89 - $16.58 $28,009 - $36,028	-2,173 Reduced 10.11%	19,319 $300,000
Q1 2021 May 06, 2021	BUY	$14.0 - $20.72 $14,280 - $21,134	1,020 Added 4.98%	21,492 $309,000
Q4 2020 Jan 28, 2021	SELL	$12.67 - $26.23 $595 - $1,232	-47 Reduced 0.23%	20,472 $402,000
Q3 2020 Nov 05, 2020	BUY	$11.92 - $15.87 $61,626 - $82,047	5,170 Added 33.68%	20,519 $266,000
Q2 2020 Aug 04, 2020	BUY	$7.53 - $14.93 $29,427 - $58,346	3,908 Added 34.16%	15,349 $224,000
Q1 2020 May 05, 2020	BUY	$5.69 - $17.78 $65,099 - $203,420	11,441 New	11,441 $97,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Arizona State Retirement System, based on Form 13F filings with the SEC.

Stay updated on Arizona State Retirement System with notifications on news.